FindTrial
Sign In

Establishment and application of innovative diagnosis and treatment model for hereditary leiomyomatous renal cell carcinoma (HLRCC)

Establishment and application of innovative diagnosis and treatment model for hereditary leiomyomatous renal cell carcinoma (HLRCC)

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037190
Enrollment
Unknown
Registered
2020-08-27
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary leiomyomatous renal cell carcinoma

Interventions

Gold Standard:Genetic testing
Index test:Metabolic&#32
small&#32
molecules

Sponsors

Renji Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Newly diagnosed renal cell carcinoma, patients agreeable to participate in this long-term follow-up study.

Exclusion criteria

Exclusion criteria: Patients' aged >70 years.

Design outcomes

Primary

MeasureTime frame
Metabolic small molecules;Tumor and blood genetic test results;Tumor burden;SEN, SPE, ACC, AUC of ROC;—

Secondary

MeasureTime frame
Overall survival OS;Progression-free survival PFS;Fumarate level;—

Countries

China

Contacts

Public ContactZhang Jin

Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Med-zhangjin@vip.sina.com+86 13661734864

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026